Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796107 · ClinicalTrials.gov registry record · Phase 2
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00796107 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 6 participants.
The verdict
NCT00796107, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.
Interventions
- DRUG Letrozole
- DRUG RG1507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-01-28 |
| Est. Completion | 2010-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796107
The ClinicalTrials.gov registry entry for NCT00796107 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Letrozole is the first listed.
NCT00796107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796107 about?
NCT00796107 is a clinical study titled "A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer". This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.
What is the current status of trial NCT00796107?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-01-28. Estimated completion is 2010-03-03.
What interventions are being tested in trial NCT00796107?
The interventions under investigation include: Letrozole (DRUG), RG1507 (DRUG).
Who is sponsoring clinical trial NCT00796107?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.